Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
July 29, 2024
LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)
August 10, 2022
APDN Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications
November 2, 2020
LineaRx Licenses CAR T Drug Candidate, Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing Platform
October 16, 2018
LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines
September 20, 2018
LineaRx Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines
September 20, 2018